MA71234A - Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide - Google Patents
Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamideInfo
- Publication number
- MA71234A MA71234A MA71234A MA71234A MA71234A MA 71234 A MA71234 A MA 71234A MA 71234 A MA71234 A MA 71234A MA 71234 A MA71234 A MA 71234A MA 71234 A MA71234 A MA 71234A
- Authority
- MA
- Morocco
- Prior art keywords
- cyanothiazolidin
- morpholinoquinoline
- oxoethyl
- carboxamide
- solid state
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263366696P | 2022-06-21 | 2022-06-21 | |
| PCT/EP2023/066559 WO2023247487A1 (fr) | 2022-06-21 | 2023-06-20 | Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide |
| EP23734210.0A EP4543877A1 (fr) | 2022-06-21 | 2023-06-20 | Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71234A true MA71234A (fr) | 2025-04-30 |
Family
ID=87047690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71234A MA71234A (fr) | 2022-06-21 | 2023-06-20 | Formes à l'état solide de n-(2-(4-cyanothiazolidin-3-yl)-2-oxoéthyl)-6-morpholinoquinoléine-4-carboxamide |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250368637A1 (fr) |
| EP (1) | EP4543877A1 (fr) |
| JP (1) | JP2025521304A (fr) |
| KR (1) | KR20250027736A (fr) |
| CN (2) | CN120554349A (fr) |
| AU (1) | AU2023288645A1 (fr) |
| CA (1) | CA3260370A1 (fr) |
| CL (1) | CL2024003894A1 (fr) |
| IL (1) | IL317722A (fr) |
| MA (1) | MA71234A (fr) |
| MX (1) | MX2024015644A (fr) |
| WO (1) | WO2023247487A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026119802A1 (fr) | 2024-12-02 | 2026-06-11 | Astrazeneca Ab | Schéma posologique pour le traitement de conditions médiées par la fap |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1760076A1 (fr) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | Inhibiteur de FAP |
| CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
| UY39569A (es) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
-
2023
- 2023-06-20 AU AU2023288645A patent/AU2023288645A1/en active Pending
- 2023-06-20 CN CN202510664265.XA patent/CN120554349A/zh active Pending
- 2023-06-20 WO PCT/EP2023/066559 patent/WO2023247487A1/fr not_active Ceased
- 2023-06-20 US US18/871,230 patent/US20250368637A1/en active Pending
- 2023-06-20 IL IL317722A patent/IL317722A/en unknown
- 2023-06-20 JP JP2024573909A patent/JP2025521304A/ja active Pending
- 2023-06-20 EP EP23734210.0A patent/EP4543877A1/fr active Pending
- 2023-06-20 MA MA71234A patent/MA71234A/fr unknown
- 2023-06-20 CN CN202380047913.6A patent/CN119585266A/zh active Pending
- 2023-06-20 KR KR1020257002002A patent/KR20250027736A/ko active Pending
- 2023-06-20 CA CA3260370A patent/CA3260370A1/fr active Pending
-
2024
- 2024-12-16 MX MX2024015644A patent/MX2024015644A/es unknown
- 2024-12-17 CL CL2024003894A patent/CL2024003894A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023247487A1 (fr) | 2023-12-28 |
| US20250368637A1 (en) | 2025-12-04 |
| EP4543877A1 (fr) | 2025-04-30 |
| JP2025521304A (ja) | 2025-07-08 |
| IL317722A (en) | 2025-02-01 |
| KR20250027736A (ko) | 2025-02-27 |
| CN120554349A (zh) | 2025-08-29 |
| MX2024015644A (es) | 2025-02-10 |
| CN119585266A (zh) | 2025-03-07 |
| AU2023288645A1 (en) | 2025-02-13 |
| CA3260370A1 (fr) | 2023-12-28 |
| CL2024003894A1 (es) | 2025-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4161575A4 (fr) | Formes cristallines d'agents de dégradation d'irak | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| EP4384525A4 (fr) | Formes à l'état solide de rélugolix | |
| EP3923798A4 (fr) | Détermination de paramètres de modèle à l'aide d'un modèle prédictif | |
| FR26C1013I1 (fr) | Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées | |
| EP3811994A4 (fr) | Procédé d'assistance à l'expectoration pour ventilateur non invasif et ventilateur non invasif | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| EP3769531A4 (fr) | Remise à l'échelle adaptative de résolution d'image pour prédiction inter et affichage | |
| EP4026802A4 (fr) | Procédé de fabrication d'une couverture d'aérogel | |
| EP4288078A4 (fr) | Forme pharmaceutique prête à perfuser d'oxytocine | |
| EP4255431A4 (fr) | Formes solide de l'émétine | |
| EP4263488A4 (fr) | Formes solides d'un composé | |
| EP4045725A4 (fr) | Plaques structurelles et procédés de construction de structures en forme d'arc à l'aide de plaques structurelles | |
| EP4183859A4 (fr) | Composition d'agent de nettoyage incorporé à l'amylase | |
| EP4291875A4 (fr) | Détection à base de fluorescence d'entités cellulaires problématiques | |
| EP4192248A4 (fr) | Dérivés amides hybrides d'amphotéricine b | |
| EP3987395A4 (fr) | Dispositif électronique pour exécuter des instructions à l'aide de coeurs de processeur et de diverses versions d'architectures d'ensembles d'instructions | |
| MA53671A (fr) | Formes cristallines d'un agoniste du récepteur farnésoïde x | |
| MA53546A (fr) | Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide | |
| EP3950282A4 (fr) | Procédé de fabrication d'un corps moulé à la presse | |
| AU2021403827A1 (en) | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides | |
| EP4252391A4 (fr) | Gestion précise d'un comportement de résolution d'acheminement | |
| EP2047859A4 (fr) | Traitement d'une maladie ischémique à l'aide d'érythropoïétine | |
| EP4463538A4 (fr) | Méthodes de réparation de lésion intestinale à l'aide de compositions organoïdes | |
| EP3740204A4 (fr) | Formes à l'état solide de fasoracétam |